Cancer constipation: are opioids really the culprit?

Davis, Mellar P.

doi:10.1007/s00520-007-0386-9

Cited by 18 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Opioids are undoubtedly a major cause of constipation in patients with advanced disease, but we should always keep in mind the multifactorial etiology of this syndrome [12]; suitable treatment regimens should therefore be established for all palliative care patients, whether they are being prescribed opioids.…”

Section: Discussionmentioning

confidence: 99%

Clinical use of oral laxatives in palliative care services in Spain

Noguera¹,

Centeno

Librada³

et al. 2010

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical use of oral laxatives in palliative care services in Spain

Noguera¹,

Centeno

Librada³

et al. 2010

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…The patient eligibility criteria were: (1) histologically confirmed prostate cancer; (2) age 75 or less; (3) a minimum of 12 months follow-up; and (4) completion of the Functional Assessment of Cancer Therapy (FACIT)-Fatigue survey (Cella et al, 1993; Lai et al, 2003; Davis et al, 2008), Expanded Prostate Cancer Index Composite (EPIC-26; Wei et al, 2000), and the American Urological Association (AUA) prostate symptom questionnaires. Informed consent was obtained from all participants prior to participation in the study.…”

Section: Methodsmentioning

confidence: 99%

Low Incidence of Fatigue after Hypofractionated Stereotactic Body Radiation Therapy for Localized Prostate Cancer

Dash¹,

Demas²,

Uhm³

et al. 2012

Front. Oncol.

View full text Add to dashboard Cite

Background: Fatigue is a common side effect of conventional prostate cancer radiation therapy. The increased delivery precision necessitated by the high dose per fraction of stereotactic body radiation therapy (SBRT) offers the potential of reduce target volumes and hence the exposure of normal tissues to high radiation doses. Herein, we examine the level of fatigue associated with SBRT treatment. Methods: Forty patients with localized prostate cancer treated with hypofractionated SBRT, and a minimum of 12 months follow-up were included in this analysis. Self-reported fatigue and other quality of life measures were assessed at baseline and at 1, 3, 6, 9, and 12 months post-SBRT. Results: Mean levels of fatigue were elevated at 1 month post-SBRT compared to baseline values (P = 0.02). Fatigue at the 3-month follow-up and later were higher but not statistically significantly different compared to baseline. African-American patients reported higher fatigue post-SBRT than Caucasian patients. Fatigue was correlated with hormonal symptoms as measured by the Expanded Prostate Cancer Index Composite (EPIC) quality of life questionnaire, but not with urinary, bowel, or sexual symptoms. Age, co-morbidities, smoking, prostate specific antigen (PSA) levels, testosterone levels, tumor stage, and treatment variables were not associated with fatigue. Conclusion: This is the first study to investigate fatigue as a side effect of SBRT. In contrast to standard radiation therapy, results suggest SBRT-related fatigue is short-term rather than a long-term side effect of SBRT. These results also suggest post-SBRT fatigue to be a more frequent complication in African-Americans than Caucasians.

show abstract

“…Klinik uygulamada konstipasyonun tanımlanmasında "evet/hayır" yanıtının yetersiz olduğu, hastanın kabızlığını 0 ile 10 arasında bir puan vererek değer-lendirmesinin daha yararlı olabileceği belirtilmektedir (36) . Yapılan başka bir araştırmada, laksatif kullanı-larak tedavi edilen kanser hastalarının %70'inde konstipasyonun semptomatik olarak devam ettiği belirtilmiştir (38) .…”

Section: Konstipasyonunclassified